Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

RATIONALE: Estrogen can cause the growth of breast cancer cells. Aromatase inhibitors, such as letrozole, anastrozole, and exemestane, may fight breast cancer by lowering the amount of estrogen the body makes. Hormone therapy, using tamoxifen citrate, may fight breast cancer by blocking the use of estrogen by the tumor cells. It is not yet known whether aromatase inhibitors or tamoxifen citrate have less effect on memory in patients receiving treatment for breast cancer.

PURPOSE: This randomized phase III trial is studying letrozole, anastrozole, or exemestane to see how they effect memory compared with tamoxifen citrate in treating postmenopausal women with breast cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Oscar Lambret
• Treatments: Anastrozole; Citric Acid; Exemestane; Letrozole; Tamoxifen

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed breast cancer

• No metastatic disease

• Meets criteria for initiating adjuvant endocrine therapy

• Hormone receptor status:

• Estrogen receptor- and/or progesterone receptor-positive disease

PATIENT CHARACTERISTICS:

• Postmenopausal, defined as no menstruation for ≥ 1 year, confirmed by a measurement of FSH and 17-beta-estradiol

• Karnofsky performance status 80-100%

• Native speaker of French

• Beneficiary of a French Social Security insurance plan

• No prior cognitive disorders

• No depression or other confirmed active psychiatric disease

• Able to undergo the medical monitoring of the trial due to geographic, social or psychological reasons

• No personal or family history of thromboembolic disease

PRIOR CONCURRENT THERAPY:

• No prior adjuvant chemotherapy

• No concurrent follow-up participation on another study

• No concurrent treatment with psychotropic substances (i.e., long half life benzodiazepines, antipsychotics, anticholinesterase)